Replication Data for: Vaccination Against COvid-19 in Primary Immunodeficiencies

The dataset contains data from the VACOPID study which was conducted between 2021 and 2025. The dataset contains clinical information of 500 patients with primary immunodeficiencies, including diagnosis, use of medication, laboratory results and disease-related complications. In the VACOPID study patients with primary immunodeficiencies were vaccinated with mRNA-1273 COVID-vaccin and responses were evaluated (antibody and T-cell responses). In a subgroup of patients a 3rd vaccin was adviced and in all patients a booster vaccination. Also after these vaccinations blood samples were taken for evaluation of antibody response and T-cell responses. The dataset therefore contains data on specific anti-SARS-CoV2 antibodes before and after vaccinations, T-cell responses evaluated by IFN-gamma realease assay at various timepoints, data on neutralzing antibodes / pseudovirus neutralization tests.

Data en bronnen

Deze gegevensset heeft geen inhoud

Extra Informatie

Veld Waarde
Titel Replication Data for: Vaccination Against COvid-19 in Primary Immunodeficiencies
Omschrijving

The dataset contains data from the VACOPID study which was conducted between 2021 and 2025. The dataset contains clinical information of 500 patients with primary immunodeficiencies, including diagnosis, use of medication, laboratory results and disease-related complications. In the VACOPID study patients with primary immunodeficiencies were vaccinated with mRNA-1273 COVID-vaccin and responses were evaluated (antibody and T-cell responses). In a subgroup of patients a 3rd vaccin was adviced and in all patients a booster vaccination. Also after these vaccinations blood samples were taken for evaluation of antibody response and T-cell responses. The dataset therefore contains data on specific anti-SARS-CoV2 antibodes before and after vaccinations, T-cell responses evaluated by IFN-gamma realease assay at various timepoints, data on neutralzing antibodes / pseudovirus neutralization tests.
Keywords
Contact points
Contact point 1
URI
Naam
Contact dataset owners via DataverseNL.
Name (translations)
Email
rso@erasmusmc.nl
Identifier
URL
  1. https://doi.org/10.34894/UBWTNQ
Publisher
Publisher 1
URI
Naam
Erasmus MC
Name (translations)
Email
rso@erasmusmc.nl
URL
https://www.erasmusmc.nl/en/contact-details-and-directions
Type
Publisher note
Publisher type
Identifier
NL-EMC
Creator
Creator 1
URI
Naam
Dalm, Virgil
Name (translations)
Email
rso@erasmusmc.nl
URL
https://fdp.erasmusmc.nl/dataset/unknown
Type
Publisher note
Publisher type
Identifier
unknown
Landing page https://doi.org/10.34894/UBWTNQ
Release date 2025-12-17T23:00:00+00:00
Modification date
In Series
    Versie
    Version notes
    Identifier doi:10.34894/UBWTNQ
    Frequency
    Provenance
    Type
    Temporal coverage
    Temporal resolution
    Spatial coverage
    Spatial resolution in meters
    Access rights http://publications.europa.eu/resource/authority/access-right/RESTRICTED
    Other identifier
    Theme
    1. https://publications.europa.eu/resource/authority/data-theme/HEAL
    Taal
    1. http://id.loc.gov/vocabulary/iso639-1/en
    Documentation
    Conforms to
    Is referenced by
    Distribution
    Sample
    Analytics
    Applicable legislation
    1. http://data.europa.eu/eli/reg/2016/679/oj
    Has version
    1. 1.0
    Code values
    Coding system
    Purpose
    Health category
    Health theme
    Legal basis
    Minimum typical age
    Maximum typical age
    Number of records
    Number of records for unique individuals.
    Personal data
    Publisher note
    Publisher type
    Trusted Data Holder
    Population coverage
    Retention period
    Health data access body
    Qualified relation
    Provenance activity
    Qualified attribution
    Quality annotations
    URI https://fdp.erasmusmc.nl/dataset/18a061df-df4a-48df-933d-e62b1bcd55e2